• ATP Luminescence in Glioblastoma Research

  2026-10-05

  A source-grounded overview of ATP-based luminescent cell viability measurement in the context of p21-ELP glioblastoma research, with emphasis on assay interpretation, evidence strength, conceptual applications, comparisons with other readouts, and limitations.

• Epalrestat and the Polyol Pathway in Translational Research

  2026-10-05

  A thought-leadership analysis of how Epalrestat, an aldose reductase inhibitor, could help researchers interrogate the intersection of polyol pathway activity, fructose metabolism, oxidative stress, and disease biology—while distinguishing mechanistic rationale from validated translational evidence.

• Calpain Inhibitor I, ALLN Product Overview

  2026-10-04

  Calpain Inhibitor I, ALLN (SKU A2602) is an APExBIO research reagent documented as a cysteine-protease inhibitor for conceptual studies of apoptosis, inflammation, and ischemia-reperfusion injury. No matched paper evidence was provided, so product claims should not be treated as independently validated findings.

• Low-Molecular-Weight Inhibitors of Complement

  2026-10-03

  The reference review explains why factor B and factor D became central targets for selective inhibition of the alternative complement pathway. It connects pathway biology, drug-discovery challenges, and emerging therapeutic applications while emphasizing the distinction between biochemical activity, disease-model evidence, and clinical translation.

• Gamma-Linolenic Acid: Research Workflows

  2026-10-02

  Build reproducible GLA workflows for LTB4 signaling, inflammation, lipid-mediated cytotoxicity, and immune-response studies. This guide combines practical dosing, controls, assay selection, and troubleshooting while clearly separating evidence for GLA from newer findings on arachidonic acid.

• CCK-8 Assay: Mechanism, Workflow, and Limits

  2026-10-01

  The Cell Counting Kit-8 is a WST-8-based method for quantitative cell viability measurement, proliferation studies, and cytotoxicity testing. Its water-soluble formazan readout simplifies microplate workflows, but the signal remains a metabolic proxy that requires controls and linear-range validation.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-10-01

  Song et al. show that murine norovirus uses the host membrane-rupture protein NINJ1 to selectively release the viral NS1 protein while also promoting broader release of cellular damage-associated molecular patterns. The study connects caspase-3 cleavage, NINJ1 recruitment to viral replication sites, and NS1 sequence determinants with norovirus infection in mice, providing a mechanistic framework for unconventional viral secretion.

• TaCRVP Hijacks Tomato Catalase to Suppress Defense

  2026-09-30

  A 2026 Advanced Science study identifies TaCRVP, a cysteine-rich venom protein in Tuta absoluta oral secretions, as an effector that targets tomato SlCAT2. The protein strengthens SlCAT2 activity and stability, suppresses hydrogen peroxide signaling, and weakens jasmonic acid-associated defenses that limit insect feeding.

• N-Formimidoyl Thienamycin vs New β-Lactams

  2026-09-30

  Cullmann et al. compared N-formimidoyl thienamycin with several contemporary β-lactams in 470 clinical isolates, emphasizing spectrum, bactericidal activity, and the influence of β-lactamase production. The study established strong activity against Pseudomonas aeruginosa and Acinetobacter spp. while showing that comparative performance varied substantially among Enterobacteriaceae.

• Toremifene Versus Tamoxifen in Advanced Breast Cancer

  2026-09-29

  The 2012 Cochrane review synthesized randomized evidence comparing toremifene with tamoxifen in advanced breast cancer and found no statistically significant difference in tumor response, time to progression, overall survival, or the reported adverse outcomes. Its main contribution is a clinically focused comparison showing that apparent similarity should be interpreted as comparative non-superiority, not proof that the two endocrine therapies are biologically identical.

• CPI-613: Metabolic Stress as an Assay Variable

  2026-09-29

  CPI-613, also known as 6,8-bis(benzylsulfanyl)octanoic acid, is examined here as a mechanistic tool rather than simply a cytotoxic reagent. This guide connects mitochondrial enzyme inhibition with PDHA1-driven metabolic plasticity and shows how to design more interpretable apoptosis assays and tumor cell metabolism studies.

• FOXN1 Reprogramming of Fibroblasts into Thymic Cells

  2026-09-28

  Ma and colleagues define how FOXN1 converts mouse embryonic fibroblasts into induced thymic epithelial cells, separating early and late transcriptional events during reprogramming. Their results identify proliferation, Notch suppression, and thymocyte co-culture as experimentally useful levers for improving iTEC maturation and MHCII expression.

• Macrophages Link Intermittent Hypoxia to Pain Priming

  2026-09-28

  In a mouse model of chronic intermittent hypoxia, both male and female mice developed persistent pain-related behaviors and evidence of nociceptor priming. The study links these changes to peripheral macrophage recruitment and reports that macrophage ablation prevented priming, identifying an immune contribution to pain associated with obstructive sleep apnea (OSA).

• Targeting Fructose Metabolism in Cancer Therapy

  2026-09-27

  This review connects dysregulated fructose uptake and metabolism with aggressive tumor behavior, including metabolic adaptation, mTORC1 signaling, and impaired antitumor immunity. Its integration of cancer-statistics analysis and mechanistic literature supports testing fructose-pathway targets, while leaving clinical benefit and patient selection to be established.

• From Poly(A) Capture to Resistance Biology

  2026-09-26

  How transcriptome and metabolite evidence can illuminate cisplatin resistance—and why thoughtful eukaryotic mRNA isolation is a foundational part of translational study design.

8606 records 1/574 page Next 12345 下5页 Last page